Healius (HLS) investor relations material

Financial performance and trading update

• Group underlying EBITDA expected between $259.0m and $264.0m for FY 2026.

• Group underlying EBIT forecasted between $30.0m and $35.0m.

• Pathology volumes grew 1.2% and revenue increased 3.5% for 1H 2026; 10-month volumes down 0.4%, revenue up 2.4%.

• GP attendances declined by 1.5% for 1H 2026 and by 1.0% for January–March 2026.

• Agilex Biolabs revenue grew 13.7% year-to-date.

Cost management and regulatory impacts

• Pathology costs increased by 1.1% for 10 months to April 2026, down from 1.9% at December 2025.

• Labour cost increases from Fair Work Commission gender undervaluation findings will impact Q4 2026 by $1.8m.

• Pathology labour costs rose 0.8% for 10 months to April 2026, including Fair Work Commission increases.

Strategic review and asset optimisation

• Exploring sale of Agilex Biolabs with UBS Securities Australia Limited following unsolicited approaches.

• Agilex operates as a standalone business; sale would not affect core pathology operations.

• Update on sale process to be provided with full year results in August or earlier if required.